Individuals at higher risk include older adults with reduced stomach acid production, people with gastrointestinal conditions affecting absorption, strict vegans, and those taking medications like metformin or proton pump inhibitors
BPC-157 tends to make the most clinical sense when the injury involves tissue that can realistically remodel and recover

others take 2-3 weeks Mild injection site reactions (if applicable) are common and self-limited Phase 3: Active Healing Phase (Weeks 3-8) Progressive improvement in symptoms For musculoskeletal conditions, this is the optimal window for physical therapy and rehabilitation For GI conditions, patients often begin reintroducing previously problematic foods Phase 4: Consolidation (Weeks 9-12+) Continued structural healing Transition to maintenance dosing if appropriate Decision point for stacking with TB-500 if additional systemic support is needed Phase 5: Transition and Maintenance Tapering off peptides after goal achievement Maintenance protocols for chronic conditions (e.g., 3 months on, 1 month off) Coordination with long-term wellness strategies (nutrition, exercise, stress management) For more information on conditions that may benefit from this approach, visit my Conditions Treated page

Key distinctions from growth hormone include [5] : Peptide lacks growth hormone receptor binding domains (specifically binding site 2) Binding site 2 is required for receptor dimerization and activation Competitive binding assays showed AOD9604 cannot compete with hGH for receptor binding Does not function as a growth hormone receptor antagonist Glucose Metabolism Preservation Unlike full hGH, which can induce insulin resistance and hyperglycemia, AOD9604 demonstrates no adverse effects on carbohydrate metabolism
Both peptides aim to reduce body weight and improve metabolic health through completely different biological mechanisms